Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trabectedin - Johnson & Johnson/University of Illinois

Drug Profile

Trabectedin - Johnson & Johnson/University of Illinois

Alternative Names: Ecteinascidin; Ecteinascidin-743; ET-743; NSC-684766; Yondelis

Latest Information Update: 21 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Illinois
  • Developer European Organisation for Research and Treatment of Cancer; Fred Hutchinson Cancer Research Center; Johnson & Johnson; Mario Negri Institute for Pharmacological Research; National Cancer Institute (USA); PharmaMar; Taiho Pharmaceutical
  • Class Antineoplastics; Dioxoles; Small molecules; Tetrahydroisoquinolines
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors; Macrophage inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer; Soft tissue sarcoma
  • Phase III Fallopian tube cancer; Peritoneal cancer
  • Phase II Leiomyosarcoma; Liposarcoma; Meningioma; Mesothelioma; Solid tumours
  • No development reported Breast cancer; Prostate cancer

Most Recent Events

  • 25 Oct 2018 Phase-II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in Germany (IV) (NCT03127215)
  • 02 Aug 2018 Phase-II clinical trials in Soft tissue sarcoma (Metastatic disease, Inoperable/Unresectable) in USA (IV) (NCT03397186)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top